The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A double-blind, double-dummy, randomized, controlled phase 3 trial of iparomlimab and tuvonralimab (QL1706) vs QL1604 as consolidation therapy following concurrent or sequential chemoradiotherapy (cCRT/sCRT) in patients (pts) with limited-stage small-cell lung cancer (LS-SCLC).
 
Linlin Wang
No Relationships to Disclose
 
Chunling Liu
No Relationships to Disclose
 
Fangling Ning
No Relationships to Disclose
 
Hongxu Liu
No Relationships to Disclose
 
Jiuwei Cui
No Relationships to Disclose
 
Wenzhong Su
No Relationships to Disclose
 
Xiang Song
No Relationships to Disclose
 
Yan Yang Wang
No Relationships to Disclose
 
Qingshan Li
No Relationships to Disclose
 
Yu Changhua
No Relationships to Disclose
 
Xianping Cheng
No Relationships to Disclose
 
Xiaomin Dang
No Relationships to Disclose
 
Furong Hao
No Relationships to Disclose
 
Tao Wei
No Relationships to Disclose
 
Yang Wei
No Relationships to Disclose
 
Huayuan Wang
Employment - QiLu Pharmaceutical
 
Jie Wang
Employment - QiLu Pharmaceutical
 
Xiusong Qiu
Employment - QiLu Pharmaceutical
 
Xiaoyan Kang
Employment - QiLu Pharmaceutical
 
Jinming Yu
No Relationships to Disclose